Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study

Peter Ueda,Viktor Wintzell,Mads Melbye,Björn Eliasson,Jonas Söderling,Soffia Gudbjörnsdottir,Kristian Hveem,Christian Jonasson,Henrik Svanström,Anders Hviid,Björn Pasternak

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association（2023）

引用 0|浏览7

暂无评分

摘要

In this analysis of nationwide data from three Nordic countries, previous safety signals indicating an increased risk of intestinal obstruction with use of DPP4 inhibitors and GLP-1 receptor agonists were not confirmed.

查看译文

关键词

Incretin-based Drugs,Type 2 Diabetes,Adverse Events

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要